Cargando…
Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion
PURPOSE: The purpose of this study was to determine the long-term outcomes of intravitreal bevacizumab (IVB) or intravitreal tissue plasminogen activator (tPA) or vitrectomy for macular edema associated with a branch retinal vein occlusion (BRVO). METHODS: This was a retrospective, interventional ca...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469473/ https://www.ncbi.nlm.nih.gov/pubmed/31043767 http://dx.doi.org/10.2147/OPTH.S195600 |
_version_ | 1783411644723888128 |
---|---|
author | Kumagai, Kazuyuki Ogino, Nobuchika Fukami, Marie Furukawa, Mariko |
author_facet | Kumagai, Kazuyuki Ogino, Nobuchika Fukami, Marie Furukawa, Mariko |
author_sort | Kumagai, Kazuyuki |
collection | PubMed |
description | PURPOSE: The purpose of this study was to determine the long-term outcomes of intravitreal bevacizumab (IVB) or intravitreal tissue plasminogen activator (tPA) or vitrectomy for macular edema associated with a branch retinal vein occlusion (BRVO). METHODS: This was a retrospective, interventional case series. Forty-one patients received a single 1.25 mg of IVB injection and followed by pro re nata protocol, 71 patients received a single intravitreal tPA, and 116 patients underwent phacovitrectomy with intraocular lens implantation. RESULTS: The baseline characteristics and follow-up periods were not significantly different among the three groups. The mean follow-up period was 55.5 months with a range of 12–160 months. Sixteen patients (39.0%) in the IVB group, 24 patients (33.8%) in the tPA group, and two patients (1.7%) in the vitrectomy group underwent additional surgeries during the follow-up period. The best-corrected visual acuity (BCVA) significantly improved in all groups at 1 year after the initial treatment (all, P<0.0001) and at the final visit (all, P<0.0001). The differences in the BCVA between the three groups were not significant at all times after the initial treatment. CONCLUSION: The three groups led to similar long-term good visual outcomes. However, additional surgeries were performed in more than 30% of patients in the IVB and tPA groups. |
format | Online Article Text |
id | pubmed-6469473 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-64694732019-05-01 Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion Kumagai, Kazuyuki Ogino, Nobuchika Fukami, Marie Furukawa, Mariko Clin Ophthalmol Original Research PURPOSE: The purpose of this study was to determine the long-term outcomes of intravitreal bevacizumab (IVB) or intravitreal tissue plasminogen activator (tPA) or vitrectomy for macular edema associated with a branch retinal vein occlusion (BRVO). METHODS: This was a retrospective, interventional case series. Forty-one patients received a single 1.25 mg of IVB injection and followed by pro re nata protocol, 71 patients received a single intravitreal tPA, and 116 patients underwent phacovitrectomy with intraocular lens implantation. RESULTS: The baseline characteristics and follow-up periods were not significantly different among the three groups. The mean follow-up period was 55.5 months with a range of 12–160 months. Sixteen patients (39.0%) in the IVB group, 24 patients (33.8%) in the tPA group, and two patients (1.7%) in the vitrectomy group underwent additional surgeries during the follow-up period. The best-corrected visual acuity (BCVA) significantly improved in all groups at 1 year after the initial treatment (all, P<0.0001) and at the final visit (all, P<0.0001). The differences in the BCVA between the three groups were not significant at all times after the initial treatment. CONCLUSION: The three groups led to similar long-term good visual outcomes. However, additional surgeries were performed in more than 30% of patients in the IVB and tPA groups. Dove Medical Press 2019-04-11 /pmc/articles/PMC6469473/ /pubmed/31043767 http://dx.doi.org/10.2147/OPTH.S195600 Text en © 2019 Kumagai et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Kumagai, Kazuyuki Ogino, Nobuchika Fukami, Marie Furukawa, Mariko Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion |
title | Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion |
title_full | Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion |
title_fullStr | Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion |
title_full_unstemmed | Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion |
title_short | Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion |
title_sort | long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469473/ https://www.ncbi.nlm.nih.gov/pubmed/31043767 http://dx.doi.org/10.2147/OPTH.S195600 |
work_keys_str_mv | AT kumagaikazuyuki longtermoutcomesofintravitreousbevacizumabortissueplasminogenactivatororvitrectomyformacularedemaduetobranchretinalveinocclusion AT oginonobuchika longtermoutcomesofintravitreousbevacizumabortissueplasminogenactivatororvitrectomyformacularedemaduetobranchretinalveinocclusion AT fukamimarie longtermoutcomesofintravitreousbevacizumabortissueplasminogenactivatororvitrectomyformacularedemaduetobranchretinalveinocclusion AT furukawamariko longtermoutcomesofintravitreousbevacizumabortissueplasminogenactivatororvitrectomyformacularedemaduetobranchretinalveinocclusion |